|         |                                                                                                                        |
|---------|------------------------------------------------------------------------------------------------------------------------|
| • | Reported net sales totaled $1.4 billion, essentially flat year-over-year. Sales grew 1.4 percent in constant currency. |

|         |                                                                        |
|---------|------------------------------------------------------------------------|
| • | GAAP earnings from continuing operations were $0.29 per diluted share. |

|         |                                                                                |
|---------|--------------------------------------------------------------------------------|
| • | Adjusted earnings1 from continuing operations totaled $0.58 per diluted share. |

|         |                                                                                              |
|---------|----------------------------------------------------------------------------------------------|
| • | Company narrows range of fiscal 2017 adjusted earnings1 guidance from continuing operations. |

|         |                                                  |
|---------|--------------------------------------------------|
| • | Consumable dental supplies decreased 2.8 percent |

|         |                                                                                                                                            |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------|
| • | Equipment sales declined 1.0 percent, reflecting strong performance in core equipment, offset by weaker performance in technology products |

----

|         |                                                                                                                                                             |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Other services and products, primarily composed of technical service, parts and labor, software support services and office supplies, decreased 1.3 percent |

|         |                                             |
|---------|---------------------------------------------|
| • | Companion animal sales improved 8.5 percent |

|         |                                                                                                                                        |
|---------|----------------------------------------------------------------------------------------------------------------------------------------|
| • | Production animal sales rose 1.3 percent, reflecting strong sales in swine, offset by lower sales in beef- and dairy-cattle categories |

----

|         |                                                                                             |
|---------|---------------------------------------------------------------------------------------------|
| • | GAAP earnings are now expected to be in the range of $1.71 to $1.77 per diluted share.  |

|         |                                                                                                          |
|---------|----------------------------------------------------------------------------------------------------------|
| • | Non-GAAP adjusted earnings1 are now expected to be in the range of $2.27 to $2.33 per diluted share. |

|         |                                                                                |
|---------|--------------------------------------------------------------------------------|
| • | Our non-GAAP adjusted earnings1 guidance excludes the after-tax impact of: |

|         |                                                                                  |
|---------|----------------------------------------------------------------------------------|
| ◦ | Deal amortization expense of approximately $27 million ($0.28 per diluted share) |

|         |                                                                                    |
|---------|------------------------------------------------------------------------------------|
| ◦ | Non-cash impairment charges of approximately $23 million ($0.24 per diluted share) |

|         |                                                                                                       |
|---------|-------------------------------------------------------------------------------------------------------|
| ◦ | Integration and business restructuring expenses of approximately $5 million ($0.05 per diluted share) |

|         |                                                                                 |
|---------|---------------------------------------------------------------------------------|
| ◦ | Transaction-related costs of approximately $2 million ($0.02 per diluted share) |

|         |                                                                                                     |
|---------|-----------------------------------------------------------------------------------------------------|
| ◦ | Benefit from cash repatriation tax adjustment of approximately $2 million ($0.03 per diluted share) |

----

----

----

|                                                                                                        |
|--------------------------------------------------------------------------------------------------------|
|                                                                                                        |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                                                                   | Three Months Ended |   | Nine Months Ended |
|                                                                                                   | January 28, 2017 |   | January 30, 2016 |   | January 28, 2017 |   | January 30, 2016 |
|                                                                                                   |   |   |   |   |   |   |   |
| Net sales                                                                                              | $ | 1,397,418 |  |   | $ | 1,400,853 |  |   | $ | 4,148,095 |  |   | $ | 3,932,933 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Gross profit                                                                                           | 329,761 |  |   | 339,864 |  |   | 965,899 |  |   | 959,007 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Operating expenses                                                                                     | 283,207 |  |   | 244,135 |  |   | 774,126 |  |   | 717,638 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Operating income from continuing operations                                                            | 46,554 |  |   | 95,729 |  |   | 191,773 |  |   | 241,369 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Other income and expense:                                                                              |   |   |   |   |   |   |   |
| Other income, net                                                                                      | 994 |  |   | 830 |  |   | 4,980 |  |   | 2,454 |  |
| Interest expense                                                                                       | (11,400 | ) |   | (10,634 | ) |   | (31,659 | ) |   | (39,931 | ) |
|                                                                                                   |   |   |   |   |   |   |   |
| Income from continuing operations before taxes                                                         | 36,148 |  |   | 85,925 |  |   | 165,094 |  |   | 203,892 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Income tax expense                                                                                     | 8,379 |  |   | 28,735 |  |   | 52,663 |  |   | 83,828 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Net income from continuing operations                                                                  | 27,769 |  |   | 57,190 |  |   | 112,431 |  |   | 120,064 |  |
| Net income (loss) from discontinued operations                                                         | (3,229 | ) |   | (750 | ) |   | (3,229 | ) |   | 1,500 |  |
| Net income                                                                                             | $ | 24,540 |  |   | $ | 56,440 |  |   | $ | 109,202 |  |   | $ | 121,564 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Basic earnings (loss) per share:                                                                       |   |   |   |   |   |   |   |
| Continuing operations                                                                                  | $ | 0.29 |  |   | $ | 0.60 |  |   | $ | 1.18 |  |   | $ | 1.23 |  |
| Discontinued operations                                                                                | (0.03 | ) |   | (0.01 | ) |   | (0.03 | ) |   | 0.01 |  |
|             Net basic earnings per share   | $ | 0.26 |  |   | $ | 0.59 |  |   | $ | 1.15 |  |   | $ | 1.24 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Diluted earnings (loss) per share:                                                                     |   |   |   |   |   |   |   |
| Continuing operations                                                                                  | $ | 0.29 |  |   | $ | 0.60 |  |   | $ | 1.17 |  |   | $ | 1.22 |  |
| Discontinued operations                                                                                | (0.03 | ) |   | (0.01 | ) |   | (0.03 | ) |   | 0.01 |  |
|             Net diluted earnings per share | $ | 0.26 |  |   | $ | 0.59 |  |   | $ | 1.14 |  |   | $ | 1.23 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Shares:                                                                                                |   |   |   |   |   |   |   |
|    Basic                                                                                | 94,737 |  |   | 95,335 |  |   | 95,252 |  |   | 97,809 |  |
|    Diluted                                                                              | 95,359 |  |   | 95,930 |  |   | 95,915 |  |   | 98,488 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Dividends declared per common share                                                                    | $ | 0.24 |  |   | $ | 0.22 |  |   | $ | 0.72 |  |   | $ | 0.66 |  |

----

|                                                                                                              |
|--------------------------------------------------------------------------------------------------------------|
|                                                                                                              |  |  |  |  |  |  |  |
|                                                                                                         | January 28, 2017 |   | April 30, 2016 |
|                                                                                                         | (Unaudited) |   |   |
| ASSETS                                                                                                       |   |   |   |
| Current assets:                                                                                              |   |   |   |
| Cash and cash equivalents                                                                                    | $ | 121,739 |  |   | $ | 137,453 |  |
| Receivables                                                                                                  | 810,155 |  |   | 796,693 |  |
| Inventory                                                                                                    | 827,057 |  |   | 722,140 |  |
| Prepaid expenses and other current assets                                                                    | 112,265 |  |   | 91,255 |  |
|            Total current assets                       | 1,871,216 |  |   | 1,747,541 |  |
| Property and equipment, net                                                                                  | 300,395 |  |   | 293,315 |  |
| Goodwill and other intangible assets                                                                         | 1,247,480 |  |   | 1,325,889 |  |
| Long-term receivables, net and other                                                                         | 174,971 |  |   | 154,059 |  |
|            Total assets                               | $ | 3,594,062 |  |   | $ | 3,520,804 |  |
|                                                                                                         |   |   |   |
| LIABILITIES AND STOCKHOLDERS' EQUITY                                                                         |   |   |   |
| Current liabilities:                                                                                         |   |   |   |
| Accounts payable                                                                                             | $ | 547,662 |  |   | $ | 566,253 |  |
| Other accrued liabilities                                                                                    | 228,037 |  |   | 226,582 |  |
| Current maturities of long-term debt                                                                         | 14,754 |  |   | 16,500 |  |
| Borrowings on revolving credit                                                                               | 198,000 |  |   | 20,000 |  |
|            Total current liabilities                  | 988,453 |  |   | 829,335 |  |
| Long-term debt                                                                                               | 1,001,775 |  |   | 1,022,155 |  |
| Other non-current liabilities                                                                                | 217,759 |  |   | 227,568 |  |
|            Total liabilities                          | 2,207,987 |  |   | 2,079,058 |  |
| Stockholders' equity                                                                                         | 1,386,075 |  |   | 1,441,746 |  |
|            Total liabilities and stockholders' equity | $ | 3,594,062 |  |   | $ | 3,520,804 |  |

----

|                                                                                                          |
|----------------------------------------------------------------------------------------------------------|
|                                                                                                          |  |  |  |  |  |  |  |
|                                                                                                          | Nine Months Ended |
|                                                                                                          | January 28, 2017 |  | January 30, 2016 |
|                                                                                                          |  |  |  |
| Operating activities:                                                                                    |  |  |  |
| Net income                                                                                               | $ | 109,202 |  |  | $ | 121,564 |  |
| Net income (loss) from discontinued operations                                                           | (3,229 | ) |  | 1,500 |  |
| Net income from continuing operations                                                                    | 112,431 |  |  | 120,064 |  |
| Adjustments to reconcile net income from continuing operations to net cash used in operating activities: |  |  |  |
| Depreciation and amortization                                                                            | 63,056 |  |  | 58,817 |  |
| Intangible asset impairment                                                                              | 36,312 |  |   | — |  |
| Non-cash employee compensation                                                                           | 17,254 |  |  | 20,587 |  |
| Change in assets and liabilities, net of acquired                                                        | (238,464 | ) |  | (247,015 | ) |
| Net cash used in operating activities- continuing operations                                             | (9,411 | ) |  | (47,547 | ) |
| Net cash used in operating activities- discontinued operations                                           | (3,229 | ) |  | (38,985 | ) |
| Net cash used in operating activities                                                                    | (12,640 | ) |  | (86,532 | ) |
| Investing activities:                                                                                    |  |  |  |
| Additions to property and equipment                                                                      | (37,457 | ) |  | (56,280 | ) |
| Acquisitions and equity investments, net of cash assumed                                                 | — |  |  | (1,106,583 | ) |
| Proceeds from sale of securities                                                                         | — |  |  | 48,744 |  |
| Other investing activities                                                                               | 35,869 |  |  | — |  |
| Net cash used in investing activities- continuing operations                                             | (1,588 | ) |  | (1,114,119 | ) |
| Net cash provided by investing activities- discontinued operations                                       | — |  |  | 714,680 |  |
| Net cash used in investing activities                                                                    | (1,588 | ) |  | (399,439 | ) |
| Financing activities:                                                                                    |  |  |  |
| Dividends paid                                                                                           | (70,947 | ) |  | (67,010 | ) |
| Repurchases of common stock                                                                              | (84,651 | ) |  | (200,000 | ) |
| Proceeds from issuance of long-term debt, net                                                            | — |  |  | 988,400 |  |
| Debt amendment costs                                                                                     | (1,266 | ) |   | — |  |
| Retirement of long-term debt                                                                             | (22,550 | ) |  | (678,250 | ) |
| Draw on revolver                                                                                         | 178,000 |  |  | 198,000 |  |
| Other financing activities                                                                               | 5,495 |  |  | 5,523 |  |
| Net cash provided by financing activities                                                                | 4,081 |  |  | 246,663 |  |
| Effect of exchange rate changes on cash                                                                  | (5,567 | ) |  | (10,251 | ) |
| Net change in cash and cash equivalents                                                                  | $ | (15,714 | ) |  | $ | (249,559 | ) |

----

|                        |
|------------------------|
|                        |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                   | January 28, 2017 |   | January 30, 2016 |   | TotalSalesGrowth |   | ForeignExchangeImpact |   | Animal HealthInternationalImpact |   | InternalGrowth |
| Three Months Ended     |   |   |   |   |   |   |   |   |   |   |   |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated net sales |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 1,064,098 |  |   | $ | 1,059,838 |  |   | 0.4 |  % |   | (2.1 | )% |   | — |  % |   | 2.5 |  % |
| Equipment and software | 249,047 |  |   | 248,779 |  |   | 0.1 |  |   | 0.2 |  |   | — |  |   | (0.1 | ) |
| Other                  | 84,273 |  |   | 92,236 |  |   | (8.6 | ) |   | (0.7 | ) |   | — |  |   | (7.9 | ) |
| Total                  | $ | 1,397,418 |  |   | $ | 1,400,853 |  |   | (0.2 | )% |   | (1.6 | )% |   | — |  % |   | 1.4 |  % |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Dental                 |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 325,181 |  |   | $ | 333,835 |  |   | (2.6 | )% |   | 0.2 |  % |   | — |  % |   | (2.8 | )% |
| Equipment and software | 230,431 |  |   | 232,334 |  |   | (0.8 | ) |   | 0.2 |  |   | — |  |   | (1.0 | ) |
| Other                  | 70,731 |  |   | 71,482 |  |   | (1.1 | ) |   | 0.2 |  |   | — |  |   | (1.3 | ) |
| Total                  | $ | 626,343 |  |   | $ | 637,651 |  |   | (1.8 | )% |   | 0.2 |  % |   | — |  % |   | (2.0 | )% |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Animal Health          |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 738,917 |  |   | $ | 726,003 |  |   | 1.8 |  % |   | (3.2 | )% |   | — |  % |   | 5.0 |  % |
| Equipment and software | 18,616 |  |   | 16,445 |  |   | 13.2 |  |   | (0.2 | ) |   | — |  |   | 13.4 |  |
| Other                  | 5,044 |  |   | 7,265 |  |   | (30.6 | ) |   | (10.9 | ) |   | — |  |   | (19.7 | ) |
| Total                  | $ | 762,577 |  |   | $ | 749,713 |  |   | 1.7 |  % |   | (3.2 | )% |   | — |  % |   | 4.9 |  % |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Corporate              |   |   |   |   |   |   |   |   |   |   |   |
| Other                  | $ | 8,498 |  |   | $ | 13,489 |  |   | (37.0 | )% |   | — |  % |   | — |  % |   | (37.0 | )% |
| Total                  | $ | 8,498 |  |   | $ | 13,489 |  |   | (37.0 | )% |   | — |  % |   | — |  % |   | (37.0 | )% |
|                   |   |   |   |   |   |   |   |   |   |   |   |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Nine Months Ended      |   |   |   |   |   |   |   |   |   |   |   |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated net sales |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 3,252,551 |  |   | $ | 3,042,634 |  |   | 6.9 |  % |   | (2.2 | )% |   | 6.4 |  % |   | 2.7 |  % |
| Equipment and software | 627,187 |  |   | 610,071 |  |   | 2.8 |  |   | — |  |   | — |  |   | 2.8 |  |
| Other                  | 268,357 |  |   | 280,228 |  |   | (4.2 | ) |   | (0.8 | ) |   | (0.1 | ) |   | (3.3 | ) |
| Total                  | $ | 4,148,095 |  |   | $ | 3,932,933 |  |   | 5.5 |  % |   | (1.8 | )% |   | 4.9 |  % |   | 2.4 |  % |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Dental                 |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 982,366 |  |   | $ | 1,024,323 |  |   | (4.1 | )% |   | (0.1 | )% |   | — |  % |   | (4.0 | )% |
| Equipment and software | 586,375 |  |   | 572,771 |  |   | 2.4 |  |   | — |  |   | — |  |   | 2.4 |  |
| Other                  | 214,170 |  |   | 216,996 |  |   | (1.3 | ) |   | — |  |   | — |  |   | (1.3 | ) |
| Total                  | $ | 1,782,911 |  |   | $ | 1,814,090 |  |   | (1.7 | )% |   | — |  % |   | — |  % |   | (1.7 | )% |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Animal Health          |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 2,270,185 |  |   | $ | 2,018,311 |  |   | 12.5 |  % |   | (3.3 | )% |   | 9.6 |  % |   | 6.2 |  % |
| Equipment and software | 40,812 |  |   | 37,300 |  |   | 9.4 |  |   | (0.2 | ) |   | — |  |   | 9.6 |  |
| Other                  | 21,357 |  |   | 25,852 |  |   | (17.4 | ) |   | (8.1 | ) |   | (0.7 | ) |   | (8.6 | ) |
| Total                  | $ | 2,332,354 |  |   | $ | 2,081,463 |  |   | 12.1 |  % |   | (3.3 | )% |   | 9.3 |  % |   | 6.1 |  % |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Corporate              |   |   |   |   |   |   |   |   |   |   |   |
| Other                  | $ | 32,830 |  |   | $ | 37,380 |  |   | (12.2 | )% |   | — |  % |   | — |  % |   | (12.2 | )% |
| Total                  | $ | 32,830 |  |   | $ | 37,380 |  |   | (12.2 | )% |   | — |  % |   | — |  % |   | (12.2 | )% |

----

|                         |
|-------------------------|
|                         |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                    | Three Months Ended |   | Nine Months Ended |
|                    | January 28, 2017 |   | January 30, 2016 |   | January 28, 2017 |   | January 30, 2016 |
|                    |   |   |   |   |   |   |   |
| Operating income (loss) |   |   |   |   |   |   |   |
| Dental                  | $ | 40,018 |  |   | $ | 82,108 |  |   | $ | 177,356 |  |   | $ | 223,454 |  |
| Animal Health           | 23,777 |  |   | 25,959 |  |   | 60,460 |  |   | 64,108 |  |
| Corporate               | (17,241 | ) |   | (12,338 | ) |   | (46,043 | ) |   | (46,193 | ) |
| Total                   | $ | 46,554 |  |   | $ | 95,729 |  |   | $ | 191,773 |  |   | $ | 241,369 |  |

----

|                                                |
|------------------------------------------------|
|                                                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| For the three months ended January 28, 2017    |   | GAAP |   | Transaction-related costs |   | Deal amortization |   | Intangible asset impairment |   | Integration and business restructuring expenses |   | Accelerated debt issuance costs |   | Tax impact of cash repatriation |   | Non-GAAP |
| Operating income from continuing operations    |   | $ | 46,554 |  |   | $ | 236 |  |   | $ | 9,951 |  |   | $ | 36,312 |  |   | $ | 625 |  |   | $ | — |  |   | $ | — |  |   | $ | 93,678 |  |
| Other expense, net                             |   | (10,406 | ) |   | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | (10,406 | ) |
| Income from continuing operations before taxes |   | 36,148 |  |   | 236 |  |   | 9,951 |  |   | 36,312 |  |   | 625 |  |   | — |  |   | — |  |   | 83,272 |  |
| Income tax expense                             |   | 8,379 |  |   | 89 |  |   | 3,480 |  |   | 13,263 |  |   | 236 |  |   | — |  |   | 2,406 |  |   | 27,853 |  |
| Net income from continuing operations          |   | $ | 27,769 |  |   | $ | 147 |  |   | $ | 6,471 |  |   | $ | 23,049 |  |   | $ | 389 |  |   | $ | — |  |   | $ | (2,406 | ) |   | $ | 55,419 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Diluted EPS from continuing operations*        |   | $ | 0.29 |  |   | $ | — |  |   | $ | 0.07 |  |   | $ | 0.24 |  |   | $ | — |  |   | $ | — |  |   | $ | (0.03 | ) |   | $ | 0.58 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated operating income as a % of sales  |   | 3.3 | % |   |   |   |   |   |   |   |   |   |   |   |   |   | 6.7 | % |
| Effective tax rate                             |   | 23.2 | % |   |   |   |   |   |   |   |   |   |   |   |   |   | 33.4 | % |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| For the three months ended January 30, 2016    |   | GAAP |   | Transaction-related costs |   | Deal amortization |   | Intangible asset impairment |   | Integration and business restructuring expenses |   | Accelerated debt issuance costs |   | Tax impact of cash repatriation |   | Non-GAAP |
| Operating income from continuing operations    |   | $ | 95,729 |  |   | $ | 44 |  |   | $ | 10,793 |  |   | $ | — |  |   | $ | 1,613 |  |   | $ | — |  |   | $ | — |  |   | $ | 108,179 |  |
| Other expense, net                             |   | (9,804 | ) |   | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | (9,804 | ) |
| Income from continuing operations before taxes |   | 85,925 |  |   | 44 |  |   | 10,793 |  |   | — |  |   | 1,613 |  |   | — |  |   | — |  |   | 98,375 |  |
| Income tax expense                             |   | 28,735 |  |   | 16 |  |   | 3,872 |  |   | — |  |   | 611 |  |   | — |  |   | — |  |   | 33,234 |  |
| Net income from continuing operations          |   | $ | 57,190 |  |   | $ | 28 |  |   | $ | 6,921 |  |   | $ | — |  |   | $ | 1,002 |  |   | $ | — |  |   | $ | — |  |   | $ | 65,141 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Diluted EPS from continuing operations*        |   | $ | 0.60 |  |   | $ | — |  |   | $ | 0.07 |  |   | $ | — |  |   | $ | 0.01 |  |   | $ | — |  |   | $ | — |  |   | $ | 0.68 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated operating income as a % of sales  |   | 6.8 | % |   |   |   |   |   |   |   |   |   |   |   |   |   | 7.7 | % |
| Effective tax rate                             |   | 33.4 | % |   |   |   |   |   |   |   |   |   |   |   |   |   | 33.8 | % |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| For the nine months ended January 28, 2017     |   | GAAP |   | Transaction-related costs |   | Deal amortization |   | Intangible asset impairment |   | Integration and business restructuring expenses |   | Accelerated debt issuance costs |   | Tax impact of cash repatriation |   | Non-GAAP |
| Operating income from continuing operations    |   | $ | 191,773 |  |   | $ | 1,479 |  |   | $ | 30,212 |  |   | $ | 36,312 |  |   | $ | 6,304 |  |   | $ | — |  |   | $ | — |  |   | $ | 266,080 |  |
| Other expense, net                             |   | (26,679 | ) |   | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | (26,679 | ) |
| Income from continuing operations before taxes |   | 165,094 |  |   | 1,479 |  |   | 30,212 |  |   | 36,312 |  |   | 6,304 |  |   | — |  |   | — |  |   | 239,401 |  |
| Income tax expense                             |   | 52,663 |  |   | 558 |  |   | 10,394 |  |   | 13,263 |  |   | 2,383 |  |   | — |  |   | 2,406 |  |   | 81,667 |  |
| Net income from continuing operations          |   | $ | 112,431 |  |   | $ | 921 |  |   | $ | 19,818 |  |   | $ | 23,049 |  |   | $ | 3,921 |  |   | $ | — |  |   | $ | (2,406 | ) |   | $ | 157,734 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Diluted EPS from continuing operations*        |   | $ | 1.17 |  |   | $ | 0.01 |  |   | $ | 0.21 |  |   | $ | 0.24 |  |   | $ | 0.04 |  |   | $ | — |  |   | $ | (0.03 | ) |   | $ | 1.64 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated operating income as a % of sales  |   | 4.6 | % |   |   |   |   |   |   |   |   |   |   |   |   |   | 6.4 | % |
| Effective tax rate                             |   | 31.9 | % |   |   |   |   |   |   |   |   |   |   |   |   |   | 34.1 | % |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| For the nine months ended January 30, 2016     |   | GAAP |   | Transaction-related costs |   | Deal amortization |   | Intangible asset impairment |   | Integration and business restructuring expenses |   | Accelerated debt issuance costs |   | Tax impact of cash repatriation |   | Non-GAAP |
| Operating income from continuing operations    |   | $ | 241,369 |  |   | $ | 13,132 |  |   | $ | 28,689 |  |   | $ | — |  |   | $ | 5,196 |  |   | $ | — |  |   | $ | — |  |   | $ | 288,386 |  |
| Other expense, net                             |   | (37,477 | ) |   | — |  |   | — |  |   | — |  |   | — |  |   | 5,153 |  |   | — |  |   | (32,324 | ) |
| Income from continuing operations before taxes |   | 203,892 |  |   | 13,132 |  |   | 28,689 |  |   | — |  |   | 5,196 |  |   | 5,153 |  |   | — |  |   | 256,062 |  |
| Income tax expense                             |   | 83,828 |  |   | 3,125 |  |   | 10,182 |  |   | — |  |   | 1,965 |  |   | 1,948 |  |   | (12,300 | ) |   | 88,748 |  |
| Net income from continuing operations          |   | $ | 120,064 |  |   | $ | 10,007 |  |   | $ | 18,507 |  |   | $ | — |  |   | $ | 3,231 |  |   | $ | 3,205 |  |   | $ | 12,300 |  |   | $ | 167,314 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Diluted EPS from continuing operations*        |   | $ | 1.22 |  |   | $ | 0.10 |  |   | $ | 0.19 |  |   | $ | — |  |   | $ | 0.03 |  |   | $ | 0.03 |  |   | $ | 0.12 |  |   | $ | 1.70 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated operating income as a % of sales  |   | 6.1 | % |   |   |   |   |   |   |   |   |   |   |   |   |   | 7.3 | % |
| Effective tax rate                             |   | 41.1 | % |   |   |   |   |   |   |   |   |   |   |   |   |   | 34.7 | % |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| * May not sum due to rounding                  |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |